With a blockbuster product in Amvuttra, a clear path to sustained profitability, and a platform expanding into massive therapeutic areas like hypertension and Alzheimer's, Alnylam is a rare breed in the biotechnology sector. The company's new five-year strategy, "Alnylam 2030," focuses on scaling operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility.
Cyborg Score Rationale
The company achieved $3 billion in revenue with 81% growth year-over-year and reached profitability in 2025. For 2026, Alnylam's TTR franchise guidance of $4.4-4.7 billion represents 83% growth. However, the company expects a mid-single-digit net price decrease for Amvuttra in the U.S. in 2026, reflecting competitive pressures.
Top Insights
Achieved profitability in 2025 after 15+ years of losses, marking transition to mature commercial-stage company
Amvuttra captured 83% of product revenue in Q4 2025 with strong payer coverage (90%+ first-line) positioning for sustained growth
Expanding into massive markets (hypertension with Roche, Alzheimer's) with proprietary RNAi platform beyond rare diseases
Launching new siRELIS enzymatic-ligation manufacturing platform to reduce costs and expand capacity ($250M investment)
Named Competitors
Vyndaqel — Oral TTR stabilizer, current market leader in ATTR with 2028 patent expiration
Attruby — TTR stabilizer approved late 2024, closest competitor for first-line ATTR therapy
Wainua — RNAi silencer with major advantage from AstraZeneca's cardiovascular sales force
Recent Developments
(Feb 2026) Reported $3B revenue (81% YoY growth) and achieved profitability for full year 2025
(Jan 2026) Announced Alnylam 2030 strategy targeting ATTR leadership, innovation growth, and financial discipline
(Feb 2026) Announced $250M manufacturing facility expansion to build proprietary siRNA production platform
Open the full interactive Alnylam Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.